Abstract
Antimicrobial peptides (AMP’s) are small peptides that have evolved as part of an innate cell defense mechanism in many organisms. We are currently developing methodologies to use these molecules to control the transmission of vector borne diseases utilizing a paratransgenic strategy. In this approach, symbiotic or commensal microbes of host insects are transformed to express gene products that interfere with pathogen transmission. These genetically altered microbes are re-introduced back to the insect where expression of the engineered molecules decreases the host’s ability to transmit the pathogen. In previous work, we demonstrated that the paratransgenic expression of the AMP, cecropin A, by transformed microbes residing in the midgut of the reduviid bug, reduced carriage of the parasite, T. cruzi, substantially. In more recent work, we reported a dramatic increase in parasite killing efficiency when AMP’s are used in combination. Further, the AMP concentrations required for parasite killing are decreased by at least 10-fold. In this review, we discuss the feasibility of utilizing other AMP’s, individually or in combination, as effector molecules to control the transmission of leishmania parasites by sand flies and to control Vibriosis, a highly devastating disease in shrimp mariculture.
Keywords: Antimicrobial peptides, chagas disease, leishmaniasis, paratransgenesis, vector-borne diseases, vibriosis, pathogen transmission, cecropin A, Triatoma infestans, cytoplasmic components
Current Drug Targets
Title:Antimicrobial Peptide Delivery Strategies: Use of Recombinant Antimicrobial Peptides in Paratransgenic Control Systems
Volume: 13 Issue: 9
Author(s): Ivy Hurwitz, Annabeth Fieck and Ravi Durvasula
Affiliation:
Keywords: Antimicrobial peptides, chagas disease, leishmaniasis, paratransgenesis, vector-borne diseases, vibriosis, pathogen transmission, cecropin A, Triatoma infestans, cytoplasmic components
Abstract: Antimicrobial peptides (AMP’s) are small peptides that have evolved as part of an innate cell defense mechanism in many organisms. We are currently developing methodologies to use these molecules to control the transmission of vector borne diseases utilizing a paratransgenic strategy. In this approach, symbiotic or commensal microbes of host insects are transformed to express gene products that interfere with pathogen transmission. These genetically altered microbes are re-introduced back to the insect where expression of the engineered molecules decreases the host’s ability to transmit the pathogen. In previous work, we demonstrated that the paratransgenic expression of the AMP, cecropin A, by transformed microbes residing in the midgut of the reduviid bug, reduced carriage of the parasite, T. cruzi, substantially. In more recent work, we reported a dramatic increase in parasite killing efficiency when AMP’s are used in combination. Further, the AMP concentrations required for parasite killing are decreased by at least 10-fold. In this review, we discuss the feasibility of utilizing other AMP’s, individually or in combination, as effector molecules to control the transmission of leishmania parasites by sand flies and to control Vibriosis, a highly devastating disease in shrimp mariculture.
Export Options
About this article
Cite this article as:
Hurwitz Ivy, Fieck Annabeth and Durvasula Ravi, Antimicrobial Peptide Delivery Strategies: Use of Recombinant Antimicrobial Peptides in Paratransgenic Control Systems, Current Drug Targets 2012; 13 (9) . https://dx.doi.org/10.2174/138945012802002366
DOI https://dx.doi.org/10.2174/138945012802002366 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Myalgic Encephalomyelitis: Symptoms and Biomarkers
Current Neuropharmacology Microalbuminuria and the Hypertensive Disorders of Pregnancy
Current Hypertension Reviews Interactions of Ginkgolides A and B with a Recombinant Human Prion Protein
Protein & Peptide Letters Therapies of Hematological Malignancies: An Overview of the Potential Targets and Their Inhibitors
Current Chemical Biology Low Grade Inflammation as a Common Pathogenetic Denominator in Age-Related Diseases: Novel Drug Targets for Anti-Ageing Strategies and Successful Ageing Achievement
Current Pharmaceutical Design Prion-like Mechanisms in Alzheimer's Disease
Current Alzheimer Research Obesity: Current Treatment and Future Horizons
Mini-Reviews in Medicinal Chemistry Current Use of mTOR Inhibitors for the Treatment of Subependymal Giant Cell Astrocytomas and Epilepsy in Patients with TSC
Current Medicinal Chemistry Pharmacogenetics of Thiopurines in Inflammatory Bowel Disease
Current Pharmaceutical Design New Therapies in SLE
Recent Patents on Inflammation & Allergy Drug Discovery β-Lactams as Neuroprotective Agents
Anti-Infective Agents in Medicinal Chemistry Mass Spectrometry in the Elucidation of the Glycoproteome of Bacterial Pathogens
Current Proteomics Targeted Drug Delivery to Macrophages in Parasitic Infections
Current Drug Delivery Neurochemical and Neuropharmacological Aspects of Circadian Disruptions: An Introduction to Asynchronization
Current Neuropharmacology Editorial [ Hot Topic: Therapeutic Potential of Peptide Motifs - Part III (Executive Editor: Jean-Claude Herve) ]
Current Pharmaceutical Design Herbal Candies: A Potential Source of Health Benefits
Current Nutrition & Food Science The Emerging Role of the Cannabinoid Receptor Family in Peripheral and Neuro-immune Interactions
Current Drug Targets Nevirapine Loaded Core Shell Gold Nanoparticles by Double Emulsion Solvent Evaporation: In vitro and In vivo Evaluation
Current Drug Delivery Inhibitors of Nitrogen Oxide Species Production in Animal Models of Inflammation and Future Directions for Therapy in Inflammatory Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Polyunsaturated Fatty Acids in Pregnancy and Metabolic Syndrome: A Review
Current Pharmaceutical Biotechnology